Rédaction Africa Links 24 with Meghana Keshavan
Published on 2024-02-02 14:12:20
A huge boost in biomanufacturing is happening in North Carolina, and researchers may have found a new potential root for autoimmune diseases in women. Bristol Myers Squibb and other companies have reported their earnings for the fourth quarter and 2023, and Regeneron Pharmaceuticals and Abbvie have also reported fourth-quarter earnings. If you want to stay on top of the latest news and developments in biotech, this article covers everything you need to know.
Bristol Myers Squibb has reported its earnings for the fourth quarter and 2023, predicting total sales to increase by a “low single digit” from $45 billion in 2023. The consensus on Bristol’s growth sales is at 2%. Regeneron Pharmaceuticals and Abbvie have also reported fourth-quarter earnings. All of these reports are essential information for those keeping tabs on the industry.
Furthermore, biotech enthusiasts can also learn from Aduhelm and how to replace a singular regulator in STAT’s biotech podcast, “The Readout LOUD.” The latest news in the life sciences industry is also discussed in this podcast.
In addition to the podcast, the biomanufacturing industry is seeing a significant surge in North Carolina, rivalling Boston. Billions of dollars are being poured into North Carolina’s biomanufacturing infrastructure, as evidenced by the 2.5 million square feet of new research and development and advanced manufacturing facilities only ten minutes from the Raleigh airport. The goal is for this area, Raleigh-Durham, to become North Carolina’s hub for producing prescription drugs. The numerous factors that are less expensive in North Carolina compared to Massachusetts make it an attractive place to build technical campuses to grow biotech production capacity. This industry development is bound to have a meaningful impact on the economy of North Carolina and the biotech industry at large.
Understanding the root causes of autoimmune diseases is essential to developing effective treatments. Stanford scientists are honing in on an explanation for why women are more likely to develop autoimmune disorders than men by examining the role of an RNA molecule called Xist, which helps prevent female cells from activating both sets of their X chromosome genes. This research offers potential for new ways to monitor or treat autoimmune disease, providing groundbreaking insights into how the immune system functions.
Arene BioWorks offers a fresh model for biological innovation with a deep talent pool and generous funding. This model is shaking up the traditional approach to scientific research, and researchers need to study it closely to see if it fosters innovation and if its parts are transferable to other settings. It presents an exciting possibility for the future of biological innovation, but it still needs to be closely studied to understand its potential impact fully.
Additional news regarding the industry, such as how Medicare has different standards than the FDA, retirement of a prominent figure in Massachusetts biotech, and the settlement of opioid cases for $500 million, are also covered in this article. If you find this content engaging and informative, you might be interested in joining a secret list for an upcoming biotech newsletter. Just some food for thought.
